Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2

Scandinavian Neoadjuvant Phase III Study of Induction Chemotherapy Followed by Irradiation Alone or Surgery Plus Irradiation in NSCLC Stage IIIA/N2 (T1N2, T2N2, T3/N2).

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00273494

Enrollment

406

Registered

2006-01-09

Start date

1998-01-31

Completion date

2008-01-31

Last updated

2008-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

N2 disease, Non-small cell lung cancer, Surgery, Neoadjuvant chemotherapy

Brief summary

Hypothesis is that surgery is of benefit in locally advanced NSCLC with N2 disease. Patients are randomised to surgery or not.

Detailed description

Patients are after staging randomised to neoadj. chemotherapy followed by surgery followed by irradiation or to chemotherapy followed by irradiation. Endpoint is survival.

Interventions

PROCEDURESurgery

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Histologically verified NSCLC * Stage IIIA/N2 * age 18-75 * Lung function test allowing surgery * Mediastinoscopy performed

Exclusion criteria

* Prior chemotherapy * Prior irradiation

Design outcomes

Primary

Measure	Time frame
Survival	—

Secondary

Measure	Time frame
time to progression	—

Countries

Denmark

Contacts

Primary ContactJens B. Sorensen, MD

jbsonk@rh.dk35454372

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026